# Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)

> **NCT05603065** · PHASE4 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 32 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab + cisplatin + paclitaxel
- **DRUG:** Tislelizumab + radiotherapy

## Key facts

- **NCT ID:** NCT05603065
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-10
- **Primary completion:** 2023-10
- **Final completion:** 2024-10
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603065, "Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05603065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*